Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B
Stopped early · Phase 1/Phase 2
Conditions studied: Hemophilia B
In brief
Study of FLT180a gene therapy in adults with Hemophilia B. Up to 9 patients will be enrolled to receive a single dose of FLT180a and be followed for 52 weeks. Results will confirm the dose for a future Phase 3 study.
Key facts
- Study ID
- NCT05164471
- Run by
- Spur Therapeutics
- People needed
- 6
- Starts
- 2021-12-06
- Expected to finish
- 2023-05-31
- Last updated by the study team
- 2026-07-31
Who can join
Age: 18 and older, up to 65. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Children's Hospital of Los Angeles — Los Angeles, California, United States
- University of South Florida — Tampa, Florida, United States
- University of Michigan — Ann Arbor, Michigan, United States
- Glasgow Royal Infirmary — Glasgow, United Kingdom
- Guys Hospital — London, United Kingdom
- Royal Free London NHS Foundation Tust — London, United Kingdom
- Royal Victoria Infirmary — Newcastle, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.